Provided by Tiger Trade Technology Pte. Ltd.

Health Care Select Sector SPDR Fund

166.18
-0.0200-0.01%
Post-market: 166.190.0101+0.01%19:55 EDT
Volume:7.15M
Turnover:1.19B
Market Cap:42.64B
PE:-11.69
High:166.85
Open:166.55
Low:165.27
Close:166.20
52wk High:176.60
52wk Low:141.05
Shares:256.62M
Float Shares:256.62M
Volume Ratio:0.83
T/O Rate:2.79%
Dividend:2.45
Dividend Rate:1.47%
EPS(TTM):-14.2170
EPS(LYR):-14.2170
ROE:-9.22%
ROA:1.03%
PB:1.24
PE(LYR):-11.69

Loading ...

Yamashita Health Care Sees FY Net Y553.00m

Dow Jones
·
Sep 30

Abbvie Highlights Positive Results from the Phase 2 Apex Part B Study of Zumilokibart in Moderate to Severe Atopic Dermatitis, as a Late Breaker at Eadv 2026

THOMSON REUTERS
·
Sep 30

AbbVie Presents Phase 2 APEX Part B Data for Zumilokibart in Moderate-to-Severe Atopic Dermatitis at EADV 2026

Reuters
·
Sep 30

IHH Healthcare's Recent Weakness Likely Offers a Buying Opportunity

Dow Jones
·
Sep 30

Golden Globe Resources Sets Date and Digital Framework for 2026 AGM

TIPRANKS
·
Sep 30

Eli Lilly reports results from TRIUMPH-2 Phase 3 trial

TIPRANKS
·
Sep 30

Lilly's Experimental Drug Cuts Weight by 21% in Diabetes Trial

Reuters
·
Sep 30

Eli Lilly - Retatrutide 12 Mg Results in 49.6 Lb (20.8%) Weight Loss over 80 Weeks

THOMSON REUTERS
·
Sep 30

Lilly's Triple Agonist, Retatrutide, Delivered Substantial Weight Loss and A1c Reduction, Underscoring Its Potential Promise for People with Obesity and Type 2 Diabetes

THOMSON REUTERS
·
Sep 30

Eli Lilly - to Submit Biologics License Application for Retatrutide in Q1 2027

THOMSON REUTERS
·
Sep 30

Eli Lilly - 59.5% of Retatrutide 12 Mg Participants no Longer Meet Bmi Criteria for Obesity

THOMSON REUTERS
·
Sep 30

Healthcare Stocks Declined as Consumer Confidence Slips

Dow Jones
·
Sep 30

Health Care Roundup: Market Talk

Dow Jones
·
Sep 30

AbbVie Inc. Stock Outperforms Competitors Despite Losses on the Day

Dow Jones
·
Sep 30

Johnson: AI Providers Committed to Building Trust

THOMSON REUTERS
·
Sep 30

Johnson: We Can Keep Edge in a Safe Way

THOMSON REUTERS
·
Sep 30

Johnson: We'LL Continue to Assess and Deliberate in Coming Days

THOMSON REUTERS
·
Sep 30

US Drug Lobby Group PhRMA Names Former House Leader Cantor as CEO

Reuters
·
Sep 30

Max Healthcare updates on adjourned NCLT case involving Kalinga Hospital subsidiary

TIPRANKS
·
Sep 30

Analyst Gil Blum Lifts Immix Biopharma Price Target to $30 on Strong NEXICART-2 Data and Accelerated Commercial Path

TIPRANKS
·
Sep 30